SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings Inc ($OCTO) experienced extreme volatility, surging thousands of percentage points following news of a significant crypto treasury investment, leading to a frenzy among day traders and short sellers. The community is actively debating whether the massive gains are sustainable, with many pointing to potential dilution and insider selling, while others anticipate a continued squeeze. Speculation is high as traders look for the next stock to replicate $OCTO's meteoric rise, leading to increased attention on other low-float and crypto-related stocks.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

NBIS is trending following a multi-billion dollar agreement with Microsoft to provide AI infrastructure, fueling excitement around the company's growth potential in the AI cloud sector. The community is buzzing about the size and impact of the deal, with some suggesting it could lead to significant revenue growth and new all-time highs. Some analysts see the stock as undervalued given the broader context of increased AI infrastructure spending.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending due to a live demonstration of its solid-state batteries powering a Ducati motorcycle, showcasing faster charging and higher energy density which has sparked optimism about the technology's potential and real-world application. The community is discussing the implications of this milestone, including potential partnerships with major automakers and the possibility of a short squeeze. However, some are cautious, pointing to the long timeline for commercial production and past disappointments.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to a proposed $300M private offering of convertible senior notes, announced after a positive earnings call, leading to concerns about dilution and prompting community discussion around the timing and necessity of the offering. While some investors see it as a strategic move for long-term growth and warrant management, others view it as a deceptive practice that takes advantage of retail investors after a strong earnings report. The community is actively debating the implications of the offering, including conversion prices, capped call strikes, and potential impact on share value and future growth prospects.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

Sentage Holdings Inc is trending due to speculative interest, drawing comparisons to recent high-flying low floaters like $OCTO and $MGIH. Community chatter suggests anticipation for a potential short squeeze and after-hours momentum. Some traders are also noting the stock's low float and potential for significant price movement, while others caution about its fundamentals.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amidst growing speculation about its spectrum value, particularly after SpaceX's recent spectrum acquisition, and ahead of a potential Apple event where satellite integration could be a talking point. Community discussions revolve around potential bidding wars for Globalstar's spectrum and the company's improving financials. Bullish sentiment is fueled by hopes for new contracts and partnerships, especially with major players like Walmart and government entities, and the potential impact of the new satellite constellation.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

CASY is trending as investors discuss the potential impact of upcoming earnings on the stock's trajectory, with community members debating whether it will be a bull trap or a sustained rally. The stock's valuation and recent performance are key points of contention, as some question whether it is overvalued, while others highlight its growth potential and dividend increases. Community members are also sharing information regarding recent news, analyst ratings, and historical performance.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid community discussions around the release of documents related to Jeffrey Epstein and their potential implications for prominent figures, including Donald Trump. Sentiment appears divided, with some users expressing concern and others dismissing the relevance of the news. The stock's movement is also being attributed to broader market trends and upcoming economic data.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as traders discuss a potential breakout, fueled by recent earnings and revenue numbers despite some ongoing concerns around profitability. The community is weighing the impact of expiring warrants and speculating about potential catalysts, including a short squeeze. Some are drawing comparisons to other insurance companies and the company's relatively low market cap.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics (MCRB) is trending amid speculation of a potential acquisition offer from Nestle, with reports circulating in Swiss media, although there is no official confirmation yet. The community is actively discussing the likelihood of a deal, potential offer prices, and what it could mean for current shareholders, and some speculate that a merger is more likely. Discussions also revolve around the potential for a short squeeze, given the stock's high short interest and low float.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an early-to-mid-stage study as compared to GSK Plc’s (GSK) Shingrix vaccine. &nbsp;Herpes zoster, or shingles, is a viral infection that affects approximately one in three people in their lifetime. The disease is characterized by a painful rash and can lead to serious complications, particularly in older adults.The company evaluated the experimental vaccine in participants aged 50 to 69 years for the first part of the study, and it showed that at one month after the second vaccine dose, Z-1018 <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-positive-topline-phase-12-results-supporting">demonstrated</a> immune responses similar to those observed in the arm receiving Shingrix with a favorable tolerability profile.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DVAX">DVAX stock</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels. Shares of the company traded 6% higher on Thursday afternoon at the time of writing.<figure class="image"><img style="aspect-ratio:569/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_2_08_19_PM_png_e38a9696ce.webp" alt="DVAX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="569" height="59"><figcaption>DVAX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user suggested holding the stock patiently.<stembedurl>https://stocktwits.com/poorguy/message/626078462</stembedurl>The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year. At the dose formulation and regimen chosen for advancing to the next part of the trial, Z-1018 achieved 100% antibody production compared to Shingrix at 96.9%, the company said.Furthermore, only 12.5% of participants receiving Z-1018 at the dose reported local post-injection reactions, compared to 52.6% for Shingrix, the company said. It also noted that 27.5% participants reported body-wide reactions with the experimental vaccine, compared to 63.2% in Shingrix."These positive data mark an important inflection point for our novel shingles vaccine program as we strive to develop a product with a potential best-in-class profile with the aim to disrupt the multi-billion-dollar shingles vaccine market, which is currently dominated by one product," said CEO Ryan Spencer, referring to Shingrix.DVAX stock is down by 14% this year and by about 3% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nio-unveils-new-es8-starting-at-rmb-416800/chsj2ghRdiq">Nio Stock Rocketed 10% Today And Retail Believes It Could Hit The $10-Mark By Earnings – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medical syringe is seen with Dynavax company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Dynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday

The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year.

Equity

The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year.


Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +16.67% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Beats Q2 Earnings Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of +15.38% and -1.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates

Dynavax to Participate in Upcoming Investor Conferences

Dynavax to Participate in Upcoming Investor Conferences Dynavax to Participate in Upcoming Investor Conferences PR Newswire EMERYVILLE, Calif., Feb. 25, 2025 EMERYVILLE, Calif., Feb. 25, 2025...

Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance

Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides...

Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy

Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy PR Newswire EMERYVILLE, Calif., Feb...

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies Board of Directors at 2025 Annual Meeting

Deep Track Capital, LP, (together with its affiliates, Deep Track or we), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (Dynavax, DVAX or the Company), with...

Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025

Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025 Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host...

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Current Price	$9.70
Prev Close	$10.06
Open	$10.03
Dividend Yield	0.00%
50-Day Moving Average	$10.62
Beta	0.78
Avg. Volume	1.85M
PE Ratio	-21.20

52-Week High	$14.63
52-Week Low	$9.22
Market Capitalization	$1.18B
EPS (Annual)	$0.2048
Price to Book	2.39
Revenue Per Employee	$684,558.03
Enterprise Value/EBITDA	N/A

DVAX
Dynavax Technologies Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DVAX News

DVAX Dynavax Technologies Corp.